CA2328920A1 - Novel derivatives of 3,3-diphenylpropylamines - Google Patents

Novel derivatives of 3,3-diphenylpropylamines Download PDF

Info

Publication number
CA2328920A1
CA2328920A1 CA002328920A CA2328920A CA2328920A1 CA 2328920 A1 CA2328920 A1 CA 2328920A1 CA 002328920 A CA002328920 A CA 002328920A CA 2328920 A CA2328920 A CA 2328920A CA 2328920 A1 CA2328920 A1 CA 2328920A1
Authority
CA
Canada
Prior art keywords
diphenylpropylamines
novel
preparation
methods
pharmaceutical compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002328920A
Other languages
French (fr)
Other versions
CA2328920C (en
Inventor
Claus Meese
Bengt Sparf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Pharma GmbH
Original Assignee
Schwarz Pharma Ag
Claus Meese
Bengt Sparf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8231918&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2328920(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schwarz Pharma Ag, Claus Meese, Bengt Sparf filed Critical Schwarz Pharma Ag
Publication of CA2328920A1 publication Critical patent/CA2328920A1/en
Application granted granted Critical
Publication of CA2328920C publication Critical patent/CA2328920C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/26—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/48—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/62—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/26—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C219/28—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton having amino groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/42—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/44—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/42—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/52—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C307/00—Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C307/02—Monoamides of sulfuric acids or esters thereof, e.g. sulfamic acids

Abstract

The invention concerns novel derivatives of 3,3-diphenylpropylamines, methods for their preparation, pharmaceutical compositions containing the novel compounds, and the use of the compounds for preparing drugs. More particularly, the invention relates to novel prodrugs of antimuscarinic agents with superior pharmacokinetic properties compared to existing drugs such as oxybutynin and tolterodine, methods for their preparation, pharmaceutical compositions containing them, a method of using said compouds and compositions for the treatment of urinary incontinence, gastrointestinal hyperactivity (irritable bowel syndrome) and other smooth muscle contractile conditions.
CA002328920A 1998-05-12 1999-05-11 Novel derivatives of 3,3-diphenylpropylamines Expired - Lifetime CA2328920C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP98108608.5 1998-05-12
EP98108608A EP0957073A1 (en) 1998-05-12 1998-05-12 Novel derivatives of 3,3-diphenylpropylamines
PCT/EP1999/003212 WO1999058478A1 (en) 1998-05-12 1999-05-11 Novel derivatives of 3,3-diphenylpropylamines

Publications (2)

Publication Number Publication Date
CA2328920A1 true CA2328920A1 (en) 1999-11-18
CA2328920C CA2328920C (en) 2008-04-15

Family

ID=8231918

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002328920A Expired - Lifetime CA2328920C (en) 1998-05-12 1999-05-11 Novel derivatives of 3,3-diphenylpropylamines

Country Status (32)

Country Link
US (6) US6713464B1 (en)
EP (3) EP0957073A1 (en)
JP (3) JP3929702B2 (en)
KR (1) KR100599004B1 (en)
CN (2) CN1207268C (en)
AT (1) ATE220056T1 (en)
AU (1) AU748057B2 (en)
BR (1) BRPI9910406B8 (en)
CA (1) CA2328920C (en)
CY (1) CY2007024I1 (en)
CZ (2) CZ296605B6 (en)
DE (2) DE122007000065I2 (en)
DK (1) DK1077912T3 (en)
ES (1) ES2181443T3 (en)
FR (1) FR07C0050I2 (en)
GE (1) GEP20084461B (en)
HK (2) HK1046269B (en)
HU (2) HU230434B1 (en)
IL (1) IL139110A0 (en)
IS (1) IS2044B (en)
LU (1) LU91365I2 (en)
MX (1) MXPA00011096A (en)
NL (1) NL300293I2 (en)
NO (2) NO326872B1 (en)
NZ (1) NZ507487A (en)
PL (3) PL195581B1 (en)
PT (1) PT1077912E (en)
RU (1) RU2199525C2 (en)
SK (1) SK286052B6 (en)
TR (1) TR200003319T2 (en)
WO (1) WO1999058478A1 (en)
ZA (1) ZA200005728B (en)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0957073A1 (en) 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
DE29923134U1 (en) 1999-11-16 2000-06-29 Sanol Arznei Schwarz Gmbh Stable salts of novel derivatives of 3,3-diphenylpropylamines
SE9904850D0 (en) * 1999-12-30 1999-12-30 Pharmacia & Upjohn Ab Novel process and intermediates
DE10028443C1 (en) * 2000-06-14 2002-05-29 Sanol Arznei Schwarz Gmbh Production of optically active 3,3-diaryl-propylamine derivatives comprises six step process from 4-hydroxybenzoic acid or alkyl 4-hydroxybenzoate and cinnamic acid
DE10033016A1 (en) 2000-07-07 2002-01-24 Sanol Arznei Schwarz Gmbh Process for the preparation of 3,3-diarylpropylamines
EP1424079A1 (en) * 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine
DE10315917A1 (en) * 2003-04-08 2004-11-18 Schwarz Pharma Ag Highly pure bases of 3,3-diphenylpropylamine monoesters
DE10315878B4 (en) * 2003-04-08 2009-06-04 Schwarz Pharma Ag Device for transdermal administration of fesoterodine and use
WO2004091597A2 (en) * 2003-04-15 2004-10-28 Pharmacia & Upjohn Company Llc Method of treating irritable bowel syndrome (ibs)
BRPI0409653A (en) 2003-04-25 2006-04-25 Pharmacia & Upjohn Co Llc Halogen substituted 3,3-diphenylpropylamines (tolterodine) with antimuscarinic activity
ATE545627T1 (en) 2003-05-23 2012-03-15 Bridge Pharma Inc SMOOTH MUSCLE SPASMOLYTICS
WO2005012227A2 (en) * 2003-08-05 2005-02-10 Ranbaxy Laboratories Limited Process for preparation of 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethyl-phenol, a metabolite of tolterodine
WO2007039918A1 (en) * 2005-10-06 2007-04-12 Natco Pharma Limited Novel process for the preparation of tolterodine
JP2007169278A (en) * 2005-12-20 2007-07-05 Pfizer Prod Inc Medicinal combination for luts treatment
US8119667B2 (en) * 2005-12-29 2012-02-21 Schering-Plough Animal Health Corporation Carbonates of fenicol antibiotics
ES2350056T3 (en) * 2006-05-24 2011-01-17 Pfizer Limited PROCEDURE FOR THE PRODUCTION OF DERIVATIVES OF BENZOPIRAN-2-OL.
EP1862449A1 (en) * 2006-05-31 2007-12-05 Schwarz Pharma Ltd. A shortened synthesis of substituted hydroxymethyl phenols
MX2008015233A (en) * 2006-05-31 2008-12-12 Schwarz Pharma Ltd New synthesis of substituted hydroxymethyl phenols.
IES20060424A2 (en) * 2006-06-08 2007-10-31 Schwarz Pharma Ltd Accelerated synthesis of (3-Diisopropylamino-1-phenylpropyl)-4-(hydroxymethyl)phenol and its phenolic monoesters
DE602007008389D1 (en) * 2006-06-09 2010-09-23 Schwarz Pharma Ltd SYNTHESIS OF PHENOLIC ESTERS OF HYDROXYMETHYLPHENOLES
US7807715B2 (en) 2006-06-09 2010-10-05 Ucb Pharma Gmbh Pharmaceutical compositions comprising fesoterodine
KR101316773B1 (en) * 2006-06-09 2013-10-15 유씨비 파마 게엠베하 Stabilized pharmaceutical compositions comprising fesoterodine
CN101466695B (en) * 2006-06-12 2012-06-27 施瓦茨制药有限公司 New chiral intermediate, process for rpoducing the same and its use in the manufacture of tolerodine, fesoterodine, or the active metabolitte thereof
IES20060435A2 (en) * 2006-06-12 2007-12-12 Schwarz Pharma Ltd Shortened synthesis using paraformaldehyde or trioxane
CZ2006506A3 (en) * 2006-08-09 2007-10-03 Zentiva, A. S. Tolterodine-containing pharmaceutical composition
KR101002385B1 (en) 2006-11-17 2010-12-20 아사히 가세이 케미칼즈 가부시키가이샤 Method for producing isocyanate
TW200844080A (en) 2007-01-11 2008-11-16 Asahi Kasei Chemicals Corp Process for producing isocyanate
US20090005309A1 (en) * 2007-05-18 2009-01-01 Auspex Pharmaceuticals, Inc. Substituted piperidines
US20090005431A1 (en) * 2007-06-30 2009-01-01 Auspex Pharmaceuticals, Inc. Substituted pyrrolidines
US20090062398A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched tolterodine
US20090062385A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched fesoterodine
WO2009037569A2 (en) * 2007-09-21 2009-03-26 Actavis Group Ptc Ehf An improved process for the preparation of fesoterodine
WO2009044278A1 (en) * 2007-10-01 2009-04-09 Actavis Group Ptc Ehf Amorphous fesoterodine fumarate
EP2111223A4 (en) 2007-11-01 2012-08-15 Acucela Inc Amine derivative compounds for treating ophthalmic diseases and disorders
EP2294047A2 (en) * 2008-04-04 2011-03-16 Actavis Group PTC EHF Novel mandelate salt of fesoterodine
KR20130127553A (en) 2008-05-15 2013-11-22 아사히 가세이 케미칼즈 가부시키가이샤 Process for producing isocyanate using diaryl carbonate
BRPI0822694B1 (en) 2008-05-15 2018-11-27 Asahi Kasei Chemicals Corp process to produce an isocyanate
EP2323967A2 (en) * 2008-07-21 2011-05-25 Actavis Group PTC EHF Fesoterodine comprising a reduced amount of dehydroxyfesoterodine
JP5381086B2 (en) * 2008-10-06 2014-01-08 日本電気株式会社 Communication system and communication control method
ES2533956T3 (en) 2009-05-11 2015-04-16 Ratiopharm Gmbh Desfesoterodine in the form of a salt of tartaric acid
IT1394219B1 (en) 2009-05-15 2012-06-01 Chemi Spa METHOD OF PREPARATION OF HIGH PURITY SMOKED FESOTERODINE.
IT1394217B1 (en) 2009-05-15 2012-06-01 Chemi Spa METHOD OF PREPARATION OF FESOTERODINA AND / OR SMOKED FESOTERODINE.
EP2281801B1 (en) 2009-07-27 2014-01-08 Crystal Pharma, S.A.U. Process for obtaining 3,3-diphenylpropylamines
IT1396373B1 (en) 2009-10-29 2012-11-19 Dipharma Francis Srl PROCEDURE FOR THE PREPARATION OF FESOTERODINE.
EP2316432A1 (en) 2009-10-30 2011-05-04 ratiopharm GmbH Compound containing fesoterodine and roughage
US20110124903A1 (en) * 2009-11-20 2011-05-26 Actavis Group Ptc Ehf Solid state forms of fesoterodine intermediates
IT1397521B1 (en) * 2009-12-21 2013-01-16 Dipharma Francis Srl PROCEDURE FOR THE PREPARATION OF FESOTERODINE WITH A LOW CONTENT OF IMPURITIES.
EP2364966A1 (en) 2010-03-09 2011-09-14 LEK Pharmaceuticals d.d. Process for preparation of 3-(2-hydroxy-5-substituted phenyl)-3-phenylpropylamines, intermediates for making hydroxytolterodine
US20130172411A1 (en) 2010-03-22 2013-07-04 Cadila Healthcare Limited Stable pharmaceutical compositions comprising fesoterodine
ES2604705T3 (en) 2010-03-31 2017-03-08 Ono Pharmaceutical Co., Ltd. Preventive agent and / or remedy for hand-foot syndrome
CA2796877A1 (en) 2010-04-30 2011-11-03 Merck Sharp & Dohme Corp. Novel beta 3 adrenergic receptor agonists
US20110282094A1 (en) 2010-05-11 2011-11-17 Intas Pharmaceuticals Limited Process for preparation of phenolic monoesters of hydroxymethyl phenols
IT1401451B1 (en) * 2010-06-10 2013-07-26 Chemi Spa NEW PROCESS OF PREPARATION OF 2-HYDROXY-4-PHENYL-3,4-DIHYDRO-2H-CHROMEN-6-IL-METHANOL E (R) -2- [3- (DIISOPROPYLAMINOUS) -1-PHENYLPROPYL] -4- ( hydroxymethyl) Phenol.
WO2011158257A1 (en) 2010-06-18 2011-12-22 Panacea Biotec Ltd Preparation process of fesoterodine and intermediates
WO2012025941A2 (en) 2010-08-25 2012-03-01 Cadila Healthcare Limited Processes for the preparation of fesoterodine
US8653123B2 (en) * 2010-09-16 2014-02-18 Allergan, Inc. Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating retinal diseases
IT1403094B1 (en) 2010-12-09 2013-10-04 Dipharma Francis Srl PROCEDURE FOR THE PREPARATION OF FESOTERODINA OR ITS SALT
WO2012098560A2 (en) * 2011-01-17 2012-07-26 Msn Laboratories Limited Process for the preparation of muscarinic receptor antagonist
TWI520732B (en) 2011-01-18 2016-02-11 輝瑞有限公司 Solid molecular dispersion
US9085509B2 (en) 2011-04-07 2015-07-21 Alembic Pharmaceuticals Limited Process for preparing fesoterodine
EP2508173A1 (en) 2011-04-08 2012-10-10 LEK Pharmaceuticals d.d. Stabilized pharmaceutical composition comprising fesoterodine
EP2508175A1 (en) 2011-04-08 2012-10-10 LEK Pharmaceuticals d.d. Pharmaceutical composition comprising fesoterodine or a salt or a solvate thereof
WO2013021343A1 (en) 2011-08-05 2013-02-14 Ranbaxy Laboratories Limited Process for the optical resolution of () -3- (2 -benzyloxy- 5 - bromophenyl) - 3 - phenylpropionic
WO2013046135A1 (en) 2011-09-26 2013-04-04 Ranbaxy Laboratories Limited Process for the preparation of fesoterodine or its salts
EP2800735B1 (en) 2012-01-07 2016-03-30 Alembic Pharmaceuticals Limited Process for the preparation of fesoterodine
CN103304356B (en) * 2012-03-12 2016-01-20 北京乐威泰克医药技术有限公司 The synthetic method of azanol
CA2873721C (en) 2012-05-04 2021-06-22 Crystal Pharma, S.A.U. Process for the preparation of optically active 3,3-diphenylpropylamines
WO2013046194A2 (en) 2012-05-18 2013-04-04 Alembic Pharmaceuticals Limited The novel reference markers for fesoterodine fumarate
CA2875342C (en) 2012-06-14 2017-06-13 Ratiopharm Gmbh Desfesoterodine salts
ITMI20121232A1 (en) * 2012-07-16 2014-01-17 Cambrex Profarmaco Milano Srl PROCEDURE FOR THE PREPARATION OF 2- (3-N, N-DIISOPROPYLAMINO-1-PHENYLPROPYL) -4-HYDROXYMETHYL-PHENOL AND ITS DERIVATIVES
CZ2014400A3 (en) 2014-06-09 2015-12-16 Zentiva, K.S. Fesoterodine stabilized formulation
US9751828B2 (en) 2014-07-30 2017-09-05 Dipharma Francis S.R.L. Antimuscarinic compound having a low content of impurities
TR201721437A2 (en) 2017-12-25 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi FORMULATIONS OF FESOTHERODY PROVIDING MODIFIED EMISSION

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE766207C (en) 1940-07-08 1952-12-22 Ig Farbenindustrie Ag Process for the preparation of basic compounds of the diarylmethane series
DE925468C (en) 1941-08-13 1955-03-21 Hoechst Ag Process for the preparation of ª †, ª † -Diaryl-propyl-amines
GB624117A (en) 1946-12-07 1949-05-27 Wellcome Found Improvements in and relating to the preparation of substituted allylamines and propylamines
GB627139A (en) 1947-05-28 1949-07-29 Wellcome Found Improvements in and relating to the preparation of quaternary ammonium salts of substituted propanolamines, allylamines and propylamines
NL70759C (en) 1947-10-28
US2567245A (en) * 1948-05-10 1951-09-11 Schering Corp Aryl-(2-pyridyl)-amino alkanes and their production
US2556636A (en) * 1948-06-23 1951-06-12 Schering Corp gamma-substituted propylamine type antihistamines
DE830193C (en) 1948-11-09 1952-02-04 Farbwerke Hoechst Vormals Meis Process for the preparation of basic compounds
CH287776A (en) 1948-11-09 1952-12-15 Michael Dr Erlenbach Process for the preparation of a basic compound.
GB685696A (en) 1948-11-23 1953-01-07 Schering Corp Process for the manufacture of anti-histaminic compounds
NL74271C (en) 1949-09-05
US2676964A (en) * 1950-06-07 1954-04-27 Schering Corp 3-pyridyl propylamine antihistamine substances
US3261841A (en) * 1961-05-03 1966-07-19 Sterling Drug Inc N-substituted 1,5-iminocycloalkanes and -alkenes
US3216841A (en) * 1962-04-30 1965-11-09 Clevite Corp Metal slip casting composition
DK111894A (en) 1962-11-15
GB1025041A (en) 1964-02-21 1966-04-06 Hoechst Ag Process for the manufacture of diphenylalkylamines
GB1169945A (en) 1966-08-25 1969-11-05 Geistlich Soehne Ag Pharmaceutical Compositions containing Diphenylalkyl-amine Derivatives
GB1169944A (en) 1966-08-25 1969-11-05 Geistlich Soehne Ag Novel 3,3-Diphenylpropylamines and processes for the preparation thereof
HU200591B (en) * 1986-07-11 1990-07-28 Chinoin Gyogyszer Es Vegyeszet Process for producing new diphenyl propylamine derivatives and pharmaceutical compositions comprising such compounds
SE8800207D0 (en) 1988-01-22 1988-01-22 Kabivitrum Ab NEW AMINES, THEIR USE AND MANUFACTURING
US5382600A (en) * 1988-01-22 1995-01-17 Pharmacia Aktiebolag 3,3-diphenylpropylamines and pharmaceutical compositions thereof
US5693144A (en) * 1990-03-19 1997-12-02 3D Systems, Inc. Vibrationally enhanced stereolithographic recoating
KR950701516A (en) 1992-05-13 1995-04-28 에드워드 엘. 만델 Transdermal Administration of Oxybutynin
SE9203318D0 (en) * 1992-11-06 1992-11-06 Kabi Pharmacia Ab NOVEL 3,3-DIPHENYL PROPYLAMINES, THEIR USE AND PREPARATION
US6071970A (en) 1993-02-08 2000-06-06 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
AU7994694A (en) 1994-10-21 1996-05-15 Leiras Oy Controlled release oral delivery system containing oxybutynin
AU728395B2 (en) 1996-07-19 2001-01-11 Gunnar Aberg S(-)-tolterodine in the treatment of urinary and gastrointestinal disorders
EP0948321B1 (en) 1996-12-12 2003-10-22 Dds Drug Delivery Service Gesellschaft Zur Förderung Der Forschung In Pharmazeutischer Technologie Und Biopharmazie Mbh Preparation in form of a matrix material-auxiliary agent compound containing optionally an active substance
KR20000057548A (en) * 1996-12-13 2000-09-25 알프레드 엘. 미첼슨 Optically transmissive material and bond
SE9701144D0 (en) 1997-03-27 1997-03-27 Pharmacia & Upjohn Ab Novel compounds, their use and preparation
EP0872233A1 (en) 1997-04-14 1998-10-21 Janssen Pharmaceutica N.V. Antiretroviral compositions with improved bioavailability
WO1998056359A2 (en) 1997-06-13 1998-12-17 Roland Bodmeier Compounds which delay the release of active substances
EP0957073A1 (en) 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
CZ302630B6 (en) * 1998-08-27 2011-08-10 Pharmacia & Upjohn Ab Pharmaceutical composition containing tolterodine or tolterodine-related compound
SE9803871D0 (en) 1998-11-11 1998-11-11 Pharmacia & Upjohn Ab Therapeutic method and formulation
SE9802864D0 (en) * 1998-08-27 1998-08-27 Pharmacia & Upjohn Ab Transdermally administered tolterodine as an antimuscarinic agent for the treatment of overactive bladder
DE19922662C1 (en) * 1999-05-18 2000-12-28 Sanol Arznei Schwarz Gmbh Transdermal therapeutic system (TTS) containing tolterodine
PT1227806E (en) * 1999-11-11 2005-10-31 Pfizer Health Ab PHARMACEUTICAL FORMULA CONTAINING TOLTERODINE AND ITS UTILIZATION
DE29923134U1 (en) * 1999-11-16 2000-06-29 Sanol Arznei Schwarz Gmbh Stable salts of novel derivatives of 3,3-diphenylpropylamines
US6566537B2 (en) * 1999-12-30 2003-05-20 Pharmacia Ab Process and intermediates
SE9904850D0 (en) * 1999-12-30 1999-12-30 Pharmacia & Upjohn Ab Novel process and intermediates
DE10028443C1 (en) 2000-06-14 2002-05-29 Sanol Arznei Schwarz Gmbh Production of optically active 3,3-diaryl-propylamine derivatives comprises six step process from 4-hydroxybenzoic acid or alkyl 4-hydroxybenzoate and cinnamic acid
DE10033016A1 (en) * 2000-07-07 2002-01-24 Sanol Arznei Schwarz Gmbh Process for the preparation of 3,3-diarylpropylamines
US20030086972A1 (en) 2000-08-09 2003-05-08 Appel Leah E. Hydrogel-driven drug dosage form
AR033711A1 (en) 2001-05-09 2004-01-07 Novartis Ag PHARMACEUTICAL COMPOSITIONS
US20030027856A1 (en) 2001-06-29 2003-02-06 Aberg A.K. Gunnar Tolterodine metabolites
GB0117619D0 (en) 2001-07-19 2001-09-12 Phoqus Ltd Pharmaceutical dosage form
CA2459265A1 (en) 2001-09-04 2003-03-13 Pfizer Inc. Affinity-assay for the human erg potassium channel
JP2005506323A (en) 2001-09-05 2005-03-03 ベクトゥラ・リミテッド Functional powder for oral delivery
IL160852A0 (en) 2001-09-27 2004-08-31 Pharmacia Ab Pharmaceutical compositions for the treatment of urinary disorders
ES2315425T3 (en) * 2001-10-26 2009-04-01 PHARMACIA & UPJOHN COMPANY LLC QUATERNARY AMMONIUM COMPOUNDS AND ITS USE AS ANTIMUSCARINIC AGENTS.
CA2464217A1 (en) 2001-11-05 2003-05-15 Pharmacia & Upjohn Company Antimuscarinic aerosol
WO2003053428A1 (en) * 2001-12-20 2003-07-03 Pharmacia Corporation Controlled release dosage form having improved drug release properties
WO2003103637A2 (en) 2002-01-10 2003-12-18 Ranbaxy Laboratories Limited Modified release, multiple unit drug delivery systems
KR100540035B1 (en) 2002-02-01 2005-12-29 주식회사 태평양 Multi-stage oral drug controlled-release system
DE10224107A1 (en) 2002-05-29 2003-12-11 Gruenenthal Gmbh Combination of selected opioids with other active substances for the treatment of urinary incontinence
ITMI20021329A1 (en) 2002-06-14 2003-12-15 Recordati Chem Pharm NEW OXIALYKYLAMES REPLACED
AU2003268361A1 (en) 2002-08-30 2004-03-19 Watson Pharmaceuticals, Inc. Drug delivery system for treating urinary incontinence
WO2004031973A1 (en) * 2002-09-30 2004-04-15 Advent Networks, Inc. Implementing request/reply programming semantics using publish/subscribe middleware
DE10315878B4 (en) * 2003-04-08 2009-06-04 Schwarz Pharma Ag Device for transdermal administration of fesoterodine and use
DE10315917A1 (en) * 2003-04-08 2004-11-18 Schwarz Pharma Ag Highly pure bases of 3,3-diphenylpropylamine monoesters
BRPI0409653A (en) * 2003-04-25 2006-04-25 Pharmacia & Upjohn Co Llc Halogen substituted 3,3-diphenylpropylamines (tolterodine) with antimuscarinic activity

Also Published As

Publication number Publication date
HUP0100779A2 (en) 2001-08-28
US7384980B2 (en) 2008-06-10
CN1354737A (en) 2002-06-19
EP0957073A1 (en) 1999-11-17
HK1084099A1 (en) 2006-07-21
FR07C0050I2 (en) 2008-05-09
SK286052B6 (en) 2008-02-05
PL195581B1 (en) 2007-10-31
FR07C0050I1 (en) 2007-11-16
SK15472000A3 (en) 2001-06-11
HK1046269B (en) 2005-09-23
CY2007024I2 (en) 2010-07-28
PT1077912E (en) 2002-11-29
US20090042981A1 (en) 2009-02-12
AU748057B2 (en) 2002-05-30
CN1690041A (en) 2005-11-02
PL202489B1 (en) 2009-06-30
MXPA00011096A (en) 2002-06-04
DK1077912T3 (en) 2002-10-28
NO326872B1 (en) 2009-03-09
US7230030B2 (en) 2007-06-12
NO20005669D0 (en) 2000-11-10
CZ296605B6 (en) 2006-04-12
BRPI9910406B8 (en) 2021-05-25
GEP20084461B (en) 2008-08-25
AU4141299A (en) 1999-11-29
JP2007204481A (en) 2007-08-16
CY2007024I1 (en) 2010-07-28
US20060270738A1 (en) 2006-11-30
US20040186061A1 (en) 2004-09-23
CN100491336C (en) 2009-05-27
WO1999058478A1 (en) 1999-11-18
HU226490B1 (en) 2009-03-02
CA2328920C (en) 2008-04-15
JP4833884B2 (en) 2011-12-07
ATE220056T1 (en) 2002-07-15
TR200003319T2 (en) 2001-12-21
IL139110A0 (en) 2001-11-25
JP4658895B2 (en) 2011-03-23
ZA200005728B (en) 2001-03-05
LU91365I9 (en) 2018-12-31
CZ299721B6 (en) 2008-10-29
NO2009015I1 (en) 2009-07-17
DE69902037T2 (en) 2003-02-06
HK1046269A1 (en) 2003-01-03
US20110294882A1 (en) 2011-12-01
NZ507487A (en) 2002-11-26
ES2181443T3 (en) 2003-02-16
US8338478B2 (en) 2012-12-25
JP3929702B2 (en) 2007-06-13
HUP0100779A3 (en) 2002-11-28
JP2003519079A (en) 2003-06-17
IS5670A (en) 2000-10-17
IS2044B (en) 2005-09-15
LU91365I2 (en) 2007-11-14
KR20010082547A (en) 2001-08-30
NO2009015I2 (en) 2012-11-12
US20100256231A1 (en) 2010-10-07
US6713464B1 (en) 2004-03-30
EP1077912A1 (en) 2001-02-28
CZ20003774A3 (en) 2001-03-14
KR100599004B1 (en) 2006-07-12
EP1254890A1 (en) 2002-11-06
BR9910406A (en) 2001-01-09
EP1077912B1 (en) 2002-07-03
RU2199525C2 (en) 2003-02-27
BR9910406B1 (en) 2014-01-07
NL300293I1 (en) 2007-11-01
NO20005669L (en) 2001-01-11
NL300293I2 (en) 2008-03-03
DE122007000065I2 (en) 2010-03-25
HU230434B1 (en) 2016-06-28
HU0600760D0 (en) 2006-12-28
US7855230B2 (en) 2010-12-21
DE122007000065I1 (en) 2008-01-03
CN1207268C (en) 2005-06-22
US7985772B2 (en) 2011-07-26
JP2007084552A (en) 2007-04-05
PL347823A1 (en) 2002-04-22
PL218882B1 (en) 2015-02-27
DE69902037D1 (en) 2002-08-08

Similar Documents

Publication Publication Date Title
CA2328920A1 (en) Novel derivatives of 3,3-diphenylpropylamines
WO2000021487A3 (en) Formoterol polymorphs
HUP0200076A3 (en) C-21 modified epothilones, process for their preparation, pharmaceutical compositions containing them
HUP0203471A3 (en) Antithrombotic compound, process for their preparation, pharmaceutical compositions containing them and their use
HUP0303487A3 (en) Compositions containing 3,7-diazabicyclo [3,3,1] compounds as anthiarhythmic agents and process for preparation of the compounds
AU4434496A (en) Process for preparing star polymer compositions
IL147367A0 (en) Pyrrolidinyl and pyrrolinyl ethylamine compounds as kappa agonists, process for their preparation and pharmaceutical compositions comprising them
HUP0200343A3 (en) Phenylalaninol derivatives, process for their preparation, pharmaceutical compositions containing them and their use
HUP0201301A3 (en) Polymorphs of a crystalline azabicyclo(2,2,2)octan-3-amine citrate and their pharmaceutical compositions and process for preparation of the compounds
AU5525199A (en) N-hydroxyacylamino compounds, process for their preparation and pharmaceutical compositions containing them
AU6870600A (en) Process for the preparation of 2,3-dihydroazepine compounds
HUP0004543A3 (en) Aminopyrroline compounds, process for their preparation and pharmaceutical compositions containing them
CA2355720A1 (en) New substituted 3-phenoxy and 3-phenylalkyloxy-2-phenyl-propylamines
HUP0202106A2 (en) Thienopyranecarboxamide derivatives, process for the preparation thereof, pharmaceutical compositions containing them
CA2155802A1 (en) Enantiomerically pure pyridylcycloalkylethylamines and the salts thereof and processes for preparing them
AU2819500A (en) Process for the preparation of asymmetrical 1,4-dihydro-pyridine-dicarboxylic acid esters
FI101264B1 (en) Process for the preparation of pharmaceutical compositions containing hydrophilic polymers

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20190513